SE9804000D0 - New composition of matter - Google Patents

New composition of matter

Info

Publication number
SE9804000D0
SE9804000D0 SE9804000A SE9804000A SE9804000D0 SE 9804000 D0 SE9804000 D0 SE 9804000D0 SE 9804000 A SE9804000 A SE 9804000A SE 9804000 A SE9804000 A SE 9804000A SE 9804000 D0 SE9804000 D0 SE 9804000D0
Authority
SE
Sweden
Prior art keywords
particles
solvent
treatment
matter
formulations
Prior art date
Application number
SE9804000A
Other languages
English (en)
Inventor
Mikael Bisrat
Mustafa Demirbueker
Saeed Moshashaee
Haakan Nyqvist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804000A priority Critical patent/SE9804000D0/sv
Publication of SE9804000D0 publication Critical patent/SE9804000D0/sv
Priority to DE69930158T priority patent/DE69930158T2/de
Priority to PCT/SE1999/002154 priority patent/WO2000030614A1/en
Priority to CZ20011778A priority patent/CZ20011778A3/cs
Priority to NZ511494A priority patent/NZ511494A/en
Priority to AU20104/00A priority patent/AU767313B2/en
Priority to PT99963731T priority patent/PT1133285E/pt
Priority to CNB998136093A priority patent/CN1198592C/zh
Priority to KR1020017006444A priority patent/KR100697780B1/ko
Priority to HU0104182A priority patent/HUP0104182A2/hu
Priority to SK703-2001A priority patent/SK7032001A3/sk
Priority to DK99963731T priority patent/DK1133285T3/da
Priority to ES99963731T priority patent/ES2258865T3/es
Priority to PL99348523A priority patent/PL348523A1/xx
Priority to IL14304099A priority patent/IL143040A0/xx
Priority to CA002349633A priority patent/CA2349633C/en
Priority to AT99963731T priority patent/ATE318583T1/de
Priority to EP99963731A priority patent/EP1133285B1/en
Priority to TR2001/01424T priority patent/TR200101424T2/xx
Priority to EEP200100275A priority patent/EE200100275A/xx
Priority to US09/486,675 priority patent/US6475524B1/en
Priority to BR9915592-3A priority patent/BR9915592A/pt
Priority to SI9930881T priority patent/SI1133285T1/sl
Priority to JP2000583498A priority patent/JP4447169B2/ja
Priority to IL143040A priority patent/IL143040A/en
Priority to ZA200103946A priority patent/ZA200103946B/xx
Priority to IS5946A priority patent/IS5946A/is
Priority to NO20012514A priority patent/NO20012514L/no
Priority to CY20061100642T priority patent/CY1105609T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Saccharide Compounds (AREA)
  • Recrystallisation Techniques (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9804000A 1998-11-23 1998-11-23 New composition of matter SE9804000D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
JP2000583498A JP4447169B2 (ja) 1998-11-23 1999-11-22 アモルファス及び／又は準安定結晶領域から結晶状態に転換される粒子の製造方法
ES99963731T ES2258865T3 (es) 1998-11-23 1999-11-22 Procedimiento de produccion de particulas con una region amorfa y/o metaestable cristalina convertida a estado cristalino.
IL14304099A IL143040A0 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
CZ20011778A CZ20011778A3 (cs) 1998-11-23 1999-11-22 Způsob výroby částic s amorfní nebo/a meta-stabilní krystalickou oblastí převedenou do krystalického stavu
NZ511494A NZ511494A (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
AU20104/00A AU767313B2 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
PT99963731T PT1133285E (pt) 1998-11-23 1999-11-22 Processo para a producao de particulas com uma regiao amorfa e/ou cristalina metastavel convertida num estado cristalino
CNB998136093A CN1198592C (zh) 1998-11-23 1999-11-22 一种使无定形和/或亚稳结晶区的微粒转化为结晶态的微粒制备方法
KR1020017006444A KR100697780B1 (ko) 1998-11-23 1999-11-22 결정 상태로 전환되는 무정형 및/또는 준안정 결정 영역을갖는 입자의 제조 방법
HU0104182A HUP0104182A2 (hu) 1998-11-23 1999-11-22 Eljárás részecskék amorf és/vagy metastabil kristályos régióinak kristályos állapotba alakítására
SK703-2001A SK7032001A3 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
DK99963731T DK1133285T3 (da) 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af partikler hvor en amorf og/eller metastabil krystallinsk region omdannes til krystallinsk tilstand
DE69930158T DE69930158T2 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich
PL99348523A PL348523A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
CA002349633A CA2349633C (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
AT99963731T ATE318583T1 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich
EP99963731A EP1133285B1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
TR2001/01424T TR200101424T2 (tr) 1998-11-23 1999-11-22 Amorf ve/veya meta-kararlı kristal bölgesi kristal hale dönüştürülmüş parçacıklar üretmek için işlem.
EEP200100275A EE200100275A (et) 1998-11-23 1999-11-22 Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod
US09/486,675 US6475524B1 (en) 1998-11-23 1999-11-22 Composition of matter
BR9915592-3A BR9915592A (pt) 1998-11-23 1999-11-22 Processos para conversão das regiões cristalinas meta-estáveis e/ou amorfas de partìculas pré-formadas para um estado essencialmente cristalino para tratamento de uma condição alérgica e/ou inflamatória do nariz ou dos pulmões, para tratamento de doença pulmonar obstrutiva crÈnica (copd), rinite ou asma e para tratamento de doenças de intestino inflamatório (ibd), doença de crohn ou colite ulcerativa, formulação farmacêutica, uso da mesma, partìculas no estado essencialmente cristalino, e, partìculas de lactose mono-hidratada no estado essencialmente cristalino
SI9930881T SI1133285T1 (sl) 1998-11-23 1999-11-22 Postopek za proizvodnjo delcev z obrnjenim amorfno in/ali meta stabilnim kristalno regijo v kristalno stanje
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
ZA200103946A ZA200103946B (en) 1998-11-23 2001-05-15 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.
IS5946A IS5946A (is) 1998-11-23 2001-05-18 Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform
NO20012514A NO20012514L (no) 1998-11-23 2001-05-22 Fremgangsmate for fremstilling av partikler med en omdannet amorf og/eller meta-stabil krystallinsk region til krystallinsk tilstand
CY20061100642T CY1105609T1 (el) 1998-11-23 2006-05-17 Μια διαδικασια για παραγωγη σωματιδιων με μετατροπη μιας αμορφης και/ή μετα-σταθερης κρυσταλλικη περιοχης σε κρυσταλλικη κατασταση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Publications (1)

Publication Number Publication Date
SE9804000D0 true SE9804000D0 (sv) 1998-11-23

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Country Status (27)

Country Link
US (1) US6475524B1 (sv)
EP (1) EP1133285B1 (sv)
JP (1) JP4447169B2 (sv)
KR (1) KR100697780B1 (sv)
CN (1) CN1198592C (sv)
AT (1) ATE318583T1 (sv)
AU (1) AU767313B2 (sv)
BR (1) BR9915592A (sv)
CA (1) CA2349633C (sv)
CY (1) CY1105609T1 (sv)
CZ (1) CZ20011778A3 (sv)
DE (1) DE69930158T2 (sv)
DK (1) DK1133285T3 (sv)
EE (1) EE200100275A (sv)
ES (1) ES2258865T3 (sv)
HU (1) HUP0104182A2 (sv)
IL (2) IL143040A0 (sv)
IS (1) IS5946A (sv)
NO (1) NO20012514L (sv)
NZ (1) NZ511494A (sv)
PL (1) PL348523A1 (sv)
PT (1) PT1133285E (sv)
SE (1) SE9804000D0 (sv)
SK (1) SK7032001A3 (sv)
TR (1) TR200101424T2 (sv)
WO (1) WO2000030614A1 (sv)
ZA (1) ZA200103946B (sv)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
WO2002051381A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Substance poreuse et son procede de fabrication
US7276190B2 (en) * 2001-07-02 2007-10-02 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
AU2008331967B2 (en) * 2007-12-07 2012-10-25 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
WO2010091198A1 (en) 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
US8541451B2 (en) 2009-07-15 2013-09-24 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
EP3685835A1 (en) 2010-08-27 2020-07-29 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
PT2968313T (pt) 2013-03-15 2018-02-21 Verona Pharma Plc Combinação de fármacos
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
EP3872069A1 (en) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
CA3101475C (en) 2018-02-08 2024-02-20 Neonc Technologies, Inc. The use of monoterpene, sesquiterpene, or their derivatives to permearbilize the blood brain barrier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
EP0817620B1 (en) 1995-03-28 2002-01-30 Fidia Advanced Biopolymers, S.R.L. Nanospheres comprising a biocompatible polysaccharide
EP2036544B1 (en) 1997-03-20 2016-12-28 Merck Sharp & Dohme Corp. Dosage form of powder agglomerates

Also Published As

Publication number Publication date
DE69930158D1 (de) 2006-04-27
EE200100275A (et) 2002-10-15
NZ511494A (en) 2003-11-28
CA2349633C (en) 2009-06-02
PT1133285E (pt) 2006-06-30
JP2002530319A (ja) 2002-09-17
NO20012514D0 (no) 2001-05-22
EP1133285A1 (en) 2001-09-19
AU2010400A (en) 2000-06-13
WO2000030614A1 (en) 2000-06-02
HUP0104182A2 (hu) 2002-03-28
TR200101424T2 (tr) 2001-12-21
CY1105609T1 (el) 2010-07-28
DK1133285T3 (da) 2006-06-06
KR20010080534A (ko) 2001-08-22
CN1198592C (zh) 2005-04-27
CA2349633A1 (en) 2000-06-02
KR100697780B1 (ko) 2007-03-21
IL143040A (en) 2009-09-01
ES2258865T3 (es) 2006-09-01
CZ20011778A3 (cs) 2001-08-15
IL143040A0 (en) 2002-04-21
SK7032001A3 (en) 2001-11-06
ZA200103946B (en) 2002-10-30
US6475524B1 (en) 2002-11-05
NO20012514L (no) 2001-07-19
PL348523A1 (en) 2002-06-03
EP1133285B1 (en) 2006-03-01
JP4447169B2 (ja) 2010-04-07
IS5946A (is) 2001-05-18
BR9915592A (pt) 2001-08-07
DE69930158T2 (de) 2006-11-16
AU767313B2 (en) 2003-11-06
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
SE9804000D0 (sv) New composition of matter
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
BR0008059A (pt) Composições de valdecoxib
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
NO20025450D0 (no) Ny farmasöytisk sammensetning
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
PT1133284E (pt) Um processo para a preparacao de particulas cristalinas
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
PT782448E (pt) Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
WO1996015786A3 (en) Oral compositions containing ondansetron
EP1769797A3 (en) Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
SV2002000235A (es) Composiciones farmaceuticas que comprenden valdecoxib
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
SE9603725D0 (sv) New teatment
ATE309811T1 (de) Analgetikum aus schlangengift
FI932654A (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
NO951865L (no) Quinuclidin-derivat som substans-P antagonist